NEW YORK, Sept. 26 (GenomeWeb News) - Malvern, Pa.-based Nucleonics announced yesterday that it had received a four-year, $1.6 million grant from the National Institute of Allergy and Infectious Disease to develop RNAi reagents and methods against the Hepatitis B virus.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account? Login Now.
Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.
